ELTX

Elicio Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.56

Price (1 Year)

$14.85 $1.51

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %9.4 / %30
Non-compliant assets / Total market cap %6 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Website

Analysis (Turkish): ELTX Hissesi Caiz mi, Helal mi? Elicio Therapeutics, Inc. Katılım Analizi